Flubromazolam

Flubromazolam
Legal status
Legal status
Identifiers
CAS Number 612526-40-6 YesY
PubChem (CID) 21930924
ChemSpider 10684757 N
UNII 1BF1HN5GWD N
Chemical and physical data
Formula C17H12BrFN4
Molar mass 371.21 g·mol−1
3D model (Jmol) Interactive image
 NYesY (what is this?)

Flubromazolam[1][2] is a benzodiazepine derivative closely related to triazolam and flubromazepam that has been sold online as a designer drug.[3][4][5][6][7] Flubromazolam is reputed to be highly potent, and concerns have been raised that clonazolam and flubromazolam in particular may pose comparatively higher risks than other designer benzodiazepines, due to their ability to produce strong sedation and amnesia at oral doses of as little as 0.5 mg.[8] Life-threatening adverse reactions have been observed at doses of only 3 mg of flubromazolam.[9]

Flubromazolam has been classified as an illegal substance in Sweden after seizures by customs and police, as well as indications from the EMCDDA of wider use as a recreational drug.[10]

Flubromazolam is illegal in Switzerland as of December 2015.[11]

See also

References

  1. ↑ René Borer; Max Gerecke; Emilio Kyburz (22 October 1986). "Patent EP 0072029 B1 - Triazolobenzazepines, process and intermediates for their preparation and medicines containing them". Retrieved 6 August 2015.
  2. ↑ Jackson B. Hester Jr.; Allan D. Rudzik; Bharat V. Kamdar (November 1971). "6-Phenyl-4H-s-triazolo[4,3-a] [1,4]benzodiazepines which have central nervous system depressant activity". Journal of Medicinal Chemistry. 14 (11): 1078–1081. doi:10.1021/jm00293a015. PMID 5165540.
  3. ↑ "Flubromazolam". Cayman Chemical. Retrieved 20 November 2015.
  4. ↑ Laura M. Huppertz; Philippe Bisel; Folker Westphal; Florian Franz; Volker Auwärter; Bjoern Moosmann (July 2015). "Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites". Forensic Toxicology. 33 (2): 388–395. doi:10.1007/s11419-015-0277-6.
  5. ↑ M. Chaslot; S. El Balkhi; T. Robin; J. Morichon; N. Picard; F. Saint-Marcoux (June 2016). "Exploration des métabolites de 8 benzodiazépines de synthèse". Toxicologie Analytique et Clinique. 28 (2): S32. doi:10.1016/j.toxac.2016.03.053.
  6. ↑ Madeleine Pettersson Bergstrand; Anders Helander; Therese Hansson; Olof Beck (2016). "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Testing and Analysis. doi:10.1002/dta.2003. PMID 27366870.
  7. ↑ Høiseth, Gudrun; Tuv, Silja Skogstad; Karinen, Ritva (2016). "Blood concentrations of new designer benzodiazepines in forensic cases". Forensic Science International. doi:10.1016/j.forsciint.2016.09.006.
  8. ↑ Bjoern Moosmann; Leslie A King; Volker Auwärter (June 2015). "Designer benzodiazepines: A new challenge". World Psychiatry. 14 (2): 248. doi:10.1002/wps.20236. PMC 4471986Freely accessible. PMID 26043347.
  9. ↑ Magdalena Łukasik-Głębocka; Karina Sommerfeld; Artur Teżyk; Barbara Zielińska-Psuja; Paweł Panieński; Czesław Żaba (2016). "Flubromazolam – A new life-threatening designer benzodiazepine". Clinical Toxicology. 54 (1): 66–68. doi:10.3109/15563650.2015.1112907. PMID 26585557.
  10. ↑ "Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten.
  11. ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Der Bundesrat.


This article is issued from Wikipedia - version of the 9/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.